Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$23.21 USD
-0.86 (-3.57%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $23.20 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.21 USD
-0.86 (-3.57%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $23.20 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Brian's Big Idea on Healthcare
by Brian Bolan
Big moving drug stocks and the HealthCare Innovators service at Zacks.
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -39.19% and 0.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
by Zacks Equity Research
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
by Zacks Equity Research
bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.
3 Biotechs With Promising Gene Therapies in the Spotlight
by Ekta Bagri
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Beam Therapeutics Inc. (BEAM) points to an 81.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 139.8% in Beam Therapeutics Inc. (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.
Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical
by Zacks Equity Research
Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.
Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News
by Zacks Equity Research
Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.
BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank
by Zacks Equity Research
BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.
BEAM Focuses on Developing Gene Drug for Growth
by Zacks Equity Research
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
Down -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.